热门资讯> 正文
Essapps以11亿美元收购ARCHIMAD
2026-05-01 20:46
- Esperion Therapeutics (NASDAQ: ESPR) shares jumped about 57% in premarket trading on Friday after the drugmaker agreed to be acquired by healthcare investment firm ARCHIMED in a deal valued at up to $1.1 billion.
- Under the terms, shareholders will receive $3.16 per share in cash plus contingent value rights tied to future sales milestones worth up to $100 million, representing a 58% premium to the stock’s last close.
- The transaction, which has been approved by Esperion’s board, is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals, after which the company will go private.
- Source: Press Release
More on Esperion Therapeutics
- Esperion Therapeutics, Inc. (ESPR) Corstasis Therapeutics, - M&A Call - Slideshow
- Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio
- Esperion Therapeutics GAAP EPS of $0.22 misses by $0.05, revenue of $168.45M beats by $2.33M
推荐文章
腾讯、阿里等中概巨头业绩来袭！AI收入转化率成核心看点，这轮财报季能否助力恒科“反弹”？
港股周报 | 存储芯片持续飙升！两倍做多海力士周内狂涨64%；段永平重大调仓！清仓中国神华，大幅买入泡泡玛特
一周财经日历 | 下周重磅大事齐袭！特朗普政府或携黄仁勋访华；中概科网股财报季打响！腾讯、阿里同日放榜
美股机会日报 | “TACO”已经过时？华尔街疯狂涌入“NACHO”交易；今晚20:30！美国4月非农或创年内最大落差？
华盛早报 | 美伊突发交火！特朗普密集发声施压；英伟达官宣入股，IREN盘后一度暴涨27%
5月8日外盘头条：美国计划本周重启护航行动 特朗普给予欧盟至7月4日批准贸易协议 OpenAI与博通芯片豪赌遇冷
CoreWeave一季度末签约总电力容量3.5吉瓦 年内股价涨近80%
马斯克再下注：SpaceX IPO倒计时 拟投1190亿美元建Terafab芯片厂
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
